Big business Bioprocessing
The expansion of global biomanufacturing capacity has been the dominant topic not only since the approval of the most successful biotech drug of all time, Pfizer/BioNTech's mRNA-based COVID-19 vaccine Comirnaty.
In this issue:
- Mastering the data revolution of clinical trials
- Lead optimisation – the sequence is the key
- Automating patient-derived cell production – Interview with Nabiha Sakalyen, CEO & co-founder of Cellino Biotech Inc.
- A new purification workflow
- RTSM benefits: configuration vs. customisation
Marketing Contacts:
Andreas Macht
Tel: +49-30-264921-54
a.macht(at)biocom.de
Oliver Schnell
Tel: +49-30-264921-45
o.schnell(at)biocom.de
Editorial Contact:
Thomas Gabrielczyk
Tel: +49-30-264921-50
t.gabrielczyk(at)biocom.de